KRAS and neoplasm: This receptor is downregulated in numerous MYC-driven tumors,324–326 resulting in diminished antigen presentation and reduced recruitment of T and NK cells.213 Also oncogenic KRAS diminishes MHC-I expression,262,345 suggesting a potential collaboration between the two oncogenes in fostering tumor immune evasion.